Corvus Pharmaceuticals (CRVS) Common Equity (2015 - 2026)

Corvus Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $240.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 387.95% year-over-year to $240.7 million; the TTM figure through Mar 2026 stood at $240.7 million (up 387.95% YoY), while the FY2025 annual figure was $61.2 million, up 87.93% from the prior year.
• Common Equity was $240.7 million for Q1 2026 at Corvus Pharmaceuticals, up from $61.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $240.7 million in Q1 2026 to a low of $12.4 million in Q3 2024.
• Historically, Common Equity has averaged $65.0 million across 5 years, with a median of $51.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 71.98% in 2024, then jumped 478.35% in 2025.
• A 5-year view of Common Equity shows it stood at $56.1 million in 2022, then plunged by 31.06% to $38.7 million in 2023, then fell by 15.81% to $32.6 million in 2024, then jumped by 87.93% to $61.2 million in 2025, then jumped by 293.23% to $240.7 million in 2026.
• The last three Common Equity figures came in at $240.7 million (Q1 2026), $61.2 million (Q4 2025), and $71.8 million (Q3 2025), per Business Quant data.